Metformin Does Not Improve Outcomes for Metastatic Pancreatic Cancer

Share this content:
The addition of metformin at the dose used to treat diabetes did not improve outcomes in patients with metastatic pancreatic cancer.
The addition of metformin at the dose used to treat diabetes did not improve outcomes in patients with metastatic pancreatic cancer.

The addition of metformin at the dose used to treat diabetes did not improve outcomes in patients with metastatic pancreatic cancer treated with standard systemic therapy, according to an article published in Clinical Cancer Research.1

In this open-label randomized phase 2 trial, investigators sought to assess the safety and efficacy of metformin for treating patients with metastatic pancreatic cancer and to identify endocrine and metabolic phenotypic features or tumor molecular markers linked with sensitivity to metformin.

 

A total of 60 patients were randomly assigned (1:1) to receive standard systemic therapy with cisplatin, epirubicin, capecitabine, and gemcitabine (PEXG; 31 patients) every 4 weeks or PEXG in combination with 2 gm of oral metformin daily (29 patients).

The study's primary endpoint was 6-months progression-free survival (PFS-6) in the intention-to-treat population. It was ended for futility.

RELATED: In the Clinic: Metformin and Pancreatic Cancer

Results showed that PFS-6 was 52% (95% CI, 33 - 69) in the control group and 42% (95% CI, 24 - 59) in the metformin group (P = .61). There was no difference in disease-free survival or overall survival between the groups.

Although single-nucleotide polymorphism rs11212617 predicted glycemic response, it did not predict tumor response to metformin. Also, gene expression on tumor tissue did not predict tumor response.

Reference

  1. Reni M, Dugnani E, Cereda S, et al. (Ir)relevance of metformin treatment in patients with metastatic pancreatic cancer: an open-label randomized phase II trial. Clin Cancer Res. 2016;22(5):1076-1085. 

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters